Several candidates for the SARS-CoV-2 vaccine have entered clinical trials, and the results are eagerly anticipated. While scientists envision a global vaccine that will benefit the world’s population, in reality, political and economic factors will determine which country gets to vaccinate its citizens against COVID-19. Where does that leave Malaysia? Do we have the vaccine production capacity to mass manufacture vaccines? In the second episode of this two-part segment, we continue our conversation with Azrul Mohd Khalib, CEO, Galen Centre for Health & Social Policy, and Prof Sibrandes Poppema, TS Jeffrey Cheah Distinguished Professor, who specialises in immunopathology. Prof Poppema is also President Emeritus of the University of Groningen, the Netherlands, and Member of the Board of Sunway University, Malaysia.

Listen to Part 1 here.